Every public signal F4 has attached to this firm, with sources and cross-entity links.
Team Change
Atapir appointed Jessica Kovash as new CEO. Kovash previously scaled through LeanTaaS and has spent her career selling into the OR. The placement came through IO Associates, one of IV Accelerator's Program Partners.
AGED Diagnostics completed its 300-patient Verification Study with >95% accuracy differentiating simple steatosis from NASH and early from advanced liver fibrosis. Now launching a blinded Clinical Validation Study across 15-25 sites and a Series A.
Intelligence Ventures invested $25K in Sonaro as part of IV Accelerator Cohort I. Sonaro is AI software that turns any standard 2D ultrasound into a 3D stroke-risk screening tool in minutes.
Intelligence Ventures invested $25K in Resonata Health as part of IV Accelerator Cohort I. Resonata Health uses deterministic matching to connect patients to approved treatments and clinical trials they qualify for.
Intelligence Ventures invested $25K in HealthMosaic as part of IV Accelerator Cohort I. HealthMosaic connects bedside medical devices to a real-time data platform, with 3,467 connected beds across 16 facilities and ~$1.8M in cumulative revenue.
Intelligence Ventures invested $25K in FoXX Health as part of IV Accelerator Cohort I. FoXX Health is a whole-body symptom tracking platform built for women, using AI pattern recognition for longitudinal health data.
Intelligence Ventures invested $25K in Evidexa as part of IV Accelerator Cohort I. Evidexa simulates real patient behavior to help healthcare teams test formulary decisions and market-access strategies before launch.
Intelligence Ventures invested $25K in ePluribus Health as part of IV Accelerator Cohort I. ePluribus Health is an EHR-integrated marketplace connecting researchers to patient biospecimens and clinical data.
Intelligence Ventures invested $25K in CARA Systems as part of IV Accelerator Cohort I. CARA Systems uses AI to predict brain aneurysm rupture risk from standard CT/MR angiograms with 93% accuracy.
Intelligence Ventures invested $25K in Aperture Bio as part of IV Accelerator Cohort I. Aperture Bio is a spatial biology platform that predicts oncology drug candidate efficacy using 3D tumor models and AI.
Intelligence Ventures launched IV Accelerator, a 10-week national program for AI healthcare founders investing $25K per startup with Demo Day in NYC. First cohort of 10 companies selected from 100+ applications.
Intelligence Ventures closed Fund I in May 2026 with approximately 25 LPs after 13 months of fundraising. The fund is now raising an extension through November 20, 2026, targeting $1M first milestone to support three accelerator cohorts.